Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. A new drug class for the treatment of hypercholesterolemia

被引：1
|
作者：
Martinez de Victoria, Emilio Ortega [1 ,2 ]
机构：
[1] Univ Barcelona, IDIBAPS, Hosp Clin Barcelona, Serv Endocrinol & Nutr, Barcelona, Spain
[2] ISCIII, CIBER Fisiopatol Obesidad & Nutr CIBEROBN, Madrid, Spain
来源：
ENDOCRINOLOGIA DIABETES Y NUTRICION | 2017年 / 64卷 / 07期
关键词：
DENSITY-LIPOPROTEIN CHOLESTEROL; CORONARY-HEART-DISEASE; FAMILIAL HYPERCHOLESTEROLEMIA; CARDIOVASCULAR EVENTS; RISK; DISCONTINUATION; METAANALYSIS; ALIROCUMAB; RATIONALE; STATINS;
D O I：
10.1016/j.endinu.2017.04.005
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：341 / 344
页数：4
相关论文
共 50 条
  • [1] Proprotein convertase subtilisin/kexin type 9 (PCSK9) and inhibitors
    Avci, Ahmet
    Demir, Kenan
    Altunkeser, Bulent Behlul
    TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY, 2014, 42 : 56 - 67
  • [2] Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Inhibitors in the Treatment of Hypercholesterolemia and other Pathologies
    Seidah, Nabil G.
    CURRENT PHARMACEUTICAL DESIGN, 2013, 19 (17) : 3161 - 3172
  • [3] Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors
    Leong, Derek
    Wu, Peter E.
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2019, 191 (32) : E894 - E894
  • [4] IDENTIFICATION OF A NEW CLASS OF SMALL MOLECULE PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS
    Ferri, N.
    Lupo, M. G.
    Radi, M.
    Lebrun, J.
    ATHEROSCLEROSIS, 2020, 315 : E105 - E106
  • [5] Hyperlipidemia: Management with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors
    Shahreyar, Muhammed
    Salem, Salem A.
    Nayyar, Mannu
    George, Lekha K.
    Garg, Nadish
    Koshy, Santhosh K. G.
    JOURNAL OF THE AMERICAN BOARD OF FAMILY MEDICINE, 2018, 31 (04) : 628 - 634
  • [6] Pleiotropic Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors?
    Bittner, Vera
    CIRCULATION, 2016, 134 (22) : 1695 - 1696
  • [7] Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors to treat hypercholesterolemia: Effect on stroke risk
    Milionis, Haralampos
    Barkas, Fotios
    Ntaios, George
    Papavasileiou, Vasileios
    Vemmos, Kostantinos
    Michel, Patrick
    Elisaf, Moses
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2016, 34 : 54 - 57
  • [8] PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future
    Shimada, Yuichi J.
    Cannon, Christopher P.
    EUROPEAN HEART JOURNAL, 2015, 36 (36) : 2415 - U36
  • [9] Nonstatins and Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: Role in Non-Familial Hypercholesterolemia
    Robinson, Jennifer G.
    PROGRESS IN CARDIOVASCULAR DISEASES, 2016, 59 (02) : 165 - 171
  • [10] PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9): A Narrative Review
    Dua, Pamila
    Reeta, K. H.
    JOURNAL OF THE PRACTICE OF CARDIOVASCULAR SCIENCES, 2020, 6 (03) : 226 - 233
12345